Intranasal vaccination with probiotic Escherichia coli membrane vesicles displaying pneumococcal capsular polysaccharides elicits mucosal immunity.

ABSTRACT: A novel vaccine modality is needed to generate both systemic and mucosal immunity in the respiratory tract, where pathogens are most likely to colonize and to initiate infection. Here, we demonstrated that intranasal immunization with probiotic Escherichia coli-derived membrane vesicles displaying serotype-14 pneumococcal capsule (CPS14⁺MVs) elicited potent IgG responses without adjuvant in mice, which were comparable and significantly superior to those of the injected CPS14⁺MVs and two licensed pneumococcal vaccines (conjugate and polysaccharide types), respectively. Notably, IgA class-switch recombination occurred only with intranasal CPS14⁺MVs immunization, resulting in robust secretory IgA (SIgA) production throughout a one-year-long-term study. Further

SUBMITTER: Nakao R 

PROVIDER: S-EPMC12830806 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature